Vivesto Receives FDA Orphan Drug Designation for Cantrixil in Acute Myeloid Leukemia
Bitget2026/11/03 07:10- Vivesto received FDA orphan drug designation for Cantrixil to treat acute myeloid leukemia, supporting its development toward a Phase I trial.
- The designation offers potential development incentives, including clinical trial tax credits, with possible seven-year U.S. market exclusivity following marketing approval.
- Previously reported preclinical results showed anticancer activity, both alone and with established treatments; Cantrixil remains in preclinical development for AML.
- An earlier Phase I trial evaluated Cantrixil in ovarian cancer; the AML trial is planned.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BoE’s Greene says it is appropriate to proactively tighten our monetary policy stance
CoreWeave plans to issue at least $4 billion in investment-grade loans, falling nearly 6% after hours
According to Bloomberg, CoreWeave is seeking to refinance at least 4 billion USD through an investment-grade loan, led by Morgan Stanley and Mitsubishi UFJ, with a syndication roadshow expected to start as soon as next week. This financing continues the structure of using Nvidia chips and customer contracts as collateral, with the yield on the issuance anticipated to be around 7% to 7.5%, much lower than its junk bond yield. Following the news, CoreWeave's shares fell nearly 5.8% after hours.
Outperformed the S&P by 19.2 percentage points in one month: Berkshire (BRK.B) achieves its highest monthly relative advantage since 2010, second only to the 2008 financial crisis
As the AI trading boom subsides and technology stocks waver, one of the market’s oldest “safe havens” has once again proven its value. Berkshire Hathaway (BRK.B) has just recorded one of its most notable relative gains in over a decade.
Crypto prices
More
